KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in IntangiblesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessReceivables - NetReceivables - OtherShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Long-Term Debt Issuances (2016 - 2025)

Eli Lilly filings provide 12 years of Long-Term Debt Issuances readings, the most recent being -$200000.0 for Q4 2025.

  • On a quarterly basis, Long-Term Debt Issuances fell 100.0% to -$200000.0 in Q4 2025 year-over-year; TTM through Mar 2026 was $6.7 billion, a 41.31% decrease, with the full-year FY2025 number at $13.2 billion, up 15.33% from a year prior.
  • Long-Term Debt Issuances hit -$200000.0 in Q4 2025 for Eli Lilly, down from $6.7 billion in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $6.7 billion in Q3 2025 to a low of -$200000.0 in Q4 2025.
  • Median Long-Term Debt Issuances over the past 4 years was $4.0 billion (2023), compared with a mean of $3.4 billion.
  • Biggest five-year swings in Long-Term Debt Issuances: skyrocketed 124.53% in 2021 and later crashed 120.0% in 2024.
  • Eli Lilly's Long-Term Debt Issuances stood at $2.4 billion in 2021, then crashed by 99.98% to $500000.0 in 2023, then tumbled by 120.0% to -$100000.0 in 2024, then plummeted by 100.0% to -$200000.0 in 2025.
  • The last three reported values for Long-Term Debt Issuances were -$200000.0 (Q4 2025), $6.7 billion (Q3 2025), and $6.5 billion (Q1 2025) per Business Quant data.